The FTSE 100 on Thursday closed up 0.4% at 6,850 points,
bouncing back from losses earlier in the week. "It looks like the
market is pricing in a rising probability that a major u-turn--and
even potentially several u-turns--are likely, improving the UK's
fiscal outlook while simultaneously leaving the new PM and her
chancellor looking like they are unable to control events," says
Chris Beauchamp, chief market analyst at IG. The index's top risers
were Ocado Group, International Consolidated Airlines Group and
NatWest Group, closing up 11%, 8.0% and 7.7%, respectively.
Hays 1Q Net Fees Rose on Growth in All Major Markets
Hays PLC said Thursday that its net fees grew 19% in the first
quarter of the fiscal year, which ended on Sept. 30.
Entain 3Q Net Gambling Revenue Rose; Backs Full-Year View
Entain PLC said Thursday that its net gambling revenue increased
2% in the third quarter, and it reaffirmed full-year earnings and
easyJet Sees Narrowed FY 2022 Pretax Loss After Strong 4Q
easyJet PLC said Thursday that its headline pretax loss for the
year ended Sept. 30 is expected to be between 170 million and 190
million pounds ($188.7 million-$210.9 million) after fourth-quarter
revenue more-than doubled.
WANdisco Sees 2022 Bookings Ahead of Views as Commercial
WANdisco PLC said Thursday that bookings for the third quarter
reached a record high and that it expects bookings for the full
year to be meaningfully ahead of market consensus.
Rank Group 1Q Net Gaming Revenue Rose; Expects Pressure on
Rank Group PLC said Thursday that like-for-like net gaming
revenue, or NGR, in the first quarter saw a small rise, though it
expects further pressure on consumer spend this year.
Treatt to Report FY 2022 Revenue Rise on Growth Across Most
Treatt PLC said Thursday that it expects to report a 13% rise in
revenue for fiscal 2022 due to broad-based revenue growth across
most categories, and that tea sales declined in the period.
Zotefoams 3Q Sales Rose; Sees 2022 Revenue, Adjusted Profit
Zotefoams PLC said Thursday that sales for the third quarter
reached a record high, and that it expects full-year 2022 revenue
to rise around 24% on year, and to beat market profit views.
Smart Metering Systems CFO to Step Down
Smart Metering Systems PLC said Thursday that Chief Financial
Officer Gavin Urwin will step down on Dec. 1 to take up another
DiscoverIE 1H Sales Rose, Sees FY 2023 Earnings in Line With
DiscoverIE Group PLC said Thursday that sales for the first half
of fiscal 2023 rose, and that it is on track to deliver full-year
underlying earnings in line with the board's expectations, driven
by a robust order book.
OnTheMarket 1H Pretax Profit Rose; Confident in Full-year
OnTheMarket PLC said Thursday that pretax profit rose for the
first half of fiscal 2023, and said it was confident in meeting
full-year revenue and adjusted operating profit expectations.
Norcros 1H Like-For-Like UK Revenue Fell But Overall 1H Revenue
Norcros PLC said Thursday that like-for-like revenue in its U.K.
business fell 3% in the first half of fiscal 2023 but was 14%
higher than in 2019, and that revenue for the period rose on the
back of a robust performance.
Oxford Instruments Sees Strong 1H Revenue, Adjusted Operating
Oxford Instruments PLC said Thursday that it expects to report
strong revenue and adjusted operating profit growth for the first
half of fiscal 2023, supported by a currency tailwind, and that it
expects an improved performance in the second half.
Sabre Insurance Backs 2022 Views Amid Resilience Across
Sabre Insurance Group PLC said Thursday that it has reiterated
the guidance for the full year, as the company focuses on margin
over volumes to cover elevated levels of inflation.
Brooks Macdonald 1Q Funds Under Management Fell Slightly Due to
Brooks Macdonald Group PLC on Thursday reported a fall in funds
under management at the end of the first quarter of fiscal 2023,
driven by a further decline in global markets.
GSK Is Ahead of the Pack With Respiratory Syncytial Virus
0920 GMT - The focus and excitement around GSK's respiratory
syncytial virus vaccine is understandable given there are currently
none on the market for the disease, and blockbuster vaccines don't
come around very often, UBS analysts say in a note. Although both
GSK and Pfizer's RSV vaccines have succeeded in phase 3 trials,
GSK's trumps Pfizer's at face value, the Swiss bank's analysts say,
adding that both UBS and consensus assumes that the shot will be
approved. Overall the data looks good and may offer some upside to
consensus, UBS says. However, it might not be enough at this point
to shift focus away from GSK's litigation on recalled drug Zantac,
the analysts say. (firstname.lastname@example.org)
Contact: London NewsPlus; email@example.com
(END) Dow Jones Newswires
October 13, 2022 13:05 ET (17:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023